Aligos Therapeutics Inc (ALGS)

$12.94 -0.54 (-4.01%)
Market Cap 48.37M
Revenue (ttm) 15.53M
Net Income (ttm) -87.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -564.58%
Debt to Equity Ratio 0.00
Volume 260,400
Avg Vol 303,998
Day's Range N/A - N/A
Shares Out 3.59M
Stochastic %K 15%
Beta 2.52
Analysts Strong Sell
Price Target $103.33

Latest News on ALGS

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

Mar 3, 2025, 8:00 AM EST - 5 days ago

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

Aligos Therapeutics Announces $105 Million Private Placement Financing

Feb 12, 2025, 7:00 AM EST - 24 days ago

Aligos Therapeutics Announces $105 Million Private Placement Financing

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 13, 2024, 8:00 AM EST - 3 months ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Nov 19, 2024, 1:30 PM EST - 3 months ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Nov 6, 2024, 4:05 PM EST - 4 months ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Oct 1, 2024, 8:00 AM EDT - 5 months ago

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Aligos Therapeutics to Present at Investor Conferences in October

Sep 30, 2024, 8:00 AM EDT - 5 months ago

Aligos Therapeutics to Present at Investor Conferences in October

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Sep 19, 2024, 8:00 AM EDT - 6 months ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Sep 18, 2024, 5:00 PM EDT - 6 months ago

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Aligos Therapeutics Announces Reverse Stock Split

Aug 15, 2024, 9:00 AM EDT - 7 months ago

Aligos Therapeutics Announces Reverse Stock Split

Aligos Therapeutics Strengthens Board with Two New Independent Directors

Aug 8, 2024, 4:05 PM EDT - 7 months ago

Aligos Therapeutics Strengthens Board with Two New Independent Directors

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

Jul 22, 2024, 9:00 AM EDT - 8 months ago

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

Jul 10, 2024, 8:00 AM EDT - 8 months ago

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Jun 5, 2024, 2:30 AM EDT - 9 months ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

May 22, 2024, 4:05 PM EDT - 10 months ago

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

May 21, 2024, 8:00 AM EDT - 10 months ago

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

Apr 30, 2024, 4:05 PM EDT - 11 months ago

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Apr 25, 2024, 4:05 PM EDT - 11 months ago

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

Mar 5, 2024, 4:05 PM EST - 1 year ago

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

Feb 26, 2024, 8:00 AM EST - 1 year ago

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

Feb 20, 2024, 8:00 AM EST - 1 year ago

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

Dec 7, 2023, 4:05 PM EST - 1 year ago

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

Nov 20, 2023, 4:05 PM EST - 1 year ago

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

Nov 13, 2023, 8:00 AM EST - 1 year ago

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

Nov 10, 2023, 8:05 AM EST - 1 year ago

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

Nov 3, 2023, 4:30 PM EDT - 1 year ago

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results

Aligos Therapeutics Announces $92 Million Private Placement Financing

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Announces $92 Million Private Placement Financing

Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558

Oct 3, 2023, 7:30 AM EDT - 1 year ago

Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558

Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009

Sep 21, 2023, 7:30 AM EDT - 1 year ago

Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009

Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009

Jul 19, 2023, 7:30 AM EDT - 1 year ago

Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Jun 21, 2023, 4:30 PM EDT - 1 year ago

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Jun 7, 2023, 7:30 AM EDT - 1 year ago

Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference

May 24, 2023, 5:26 PM EDT - 1 year ago

Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference

Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos' Oligonucleotide Platform for the Treatment of Liver Diseases

May 12, 2023, 5:05 PM EDT - 1 year ago

Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos' Oligonucleotide Platform for the Treatment of Liver Diseases

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results

May 4, 2023, 4:05 PM EDT - 2 years ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results

Aligos Therapeutics to Announce First Quarter Results on May 4, 2023

Apr 27, 2023, 4:05 PM EDT - 2 years ago

Aligos Therapeutics to Announce First Quarter Results on May 4, 2023

Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Apr 11, 2023, 6:50 PM EDT - 2 years ago

Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference

Mar 29, 2023, 4:05 PM EDT - 2 years ago

Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results

Mar 9, 2023, 4:05 PM EST - 2 years ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results

Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

Feb 16, 2023, 8:00 AM EST - 2 years ago

Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference

Feb 10, 2023, 7:00 AM EST - 2 years ago

Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference

Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024

Feb 8, 2023, 4:05 PM EST - 2 years ago

Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024

Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009

Jan 5, 2023, 8:00 AM EST - 2 years ago

Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009

Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)

Dec 14, 2022, 4:05 PM EST - 2 years ago

Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)

Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD's The Liver Meeting® 2022

Nov 4, 2022, 8:05 AM EDT - 2 years ago

Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD's The Liver Meeting® 2022

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results

Nov 2, 2022, 4:05 PM EDT - 2 years ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results

Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD's The Liver Meeting® 2022

Oct 21, 2022, 9:05 AM EDT - 2 years ago

Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD's The Liver Meeting® 2022